首页 > 最新文献

Diabetes epidemiology and management最新文献

英文 中文
The role of clinical pharmacists in improving diabetic care of hospitalized heart patients 临床药师在改善住院心脏病患者糖尿病护理中的作用
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.deman.2024.100248
Sanaa Mekdad, Leenah Alsayed, Susan Alkhulaif

Introduction

Globally, diabetes is becoming an increasingly prevalent chronic illness. Managing glucose levels in patients with diabetes presents a significant challenge that requires collaboration with medical specialists. Clinical pharmacists play a crucial role in diabetes management, positively influencing patient outcomes and improving overall quality of care.

Objectives

The purpose of this research is to understand how clinical pharmacists at King Fahad Medical City impact the management of hospitalized patients with diabetes and cardiac conditions.

Method

A prospective randomized study was conducted at the Cardiac Center of King Fahad Medical City, involving patients admitted between 2019 and 2023. Participants were assigned to one of two groups: one managed by clinical pharmacists (n = 500) and the other receiving standard care without clinical pharmacists (n = 500). Patients were followed up with six months following the clinical pharmacist's intervention, as well as concurrently with data collection, baseline measurements of glycosylated hemoglobin (HbAC), fasting blood glucose (FBG), and the frequency of hypoglycemic episodes. after intervention. Concurrently, included (HbA1c), after intervention. Concurrently, collection included (HbA1c), episodes following the

Results

Both groups demonstrated a decrease in HbA1c levels. The intervention group experienced a reduction in HbA1c from 10.2 % to 8.5 % (SD = 2.2, p = 0.04). In contrast, the control group showed a decrease in HbA1c from 9.95 % to 9.05 % (SD = 1.95, p = 0.05). Additionally, fasting blood glucose (FBG) levels in the intervention group decreased by 29 mg/dL, while the decline in the control group was not statistically significant, at 9 mg/dL. The difference in HbA1c levels was statistically significant, as determined by both t-tests.

Conclusions

As a member of a multidisciplinary team, a clinical pharmacist can play a crucial role in monitoring diabetes in hospitalized patients with heart conditions. Their interventions can more effectively lower HbA1c levels and fasting blood glucose (FBG) in these patients compared to standard care.
在全球范围内,糖尿病正在成为一种日益普遍的慢性疾病。管理糖尿病患者的血糖水平是一项重大挑战,需要与医学专家合作。临床药师在糖尿病管理中发挥着至关重要的作用,积极影响患者的预后,提高整体护理质量。目的了解法赫德国王医疗城的临床药师如何影响糖尿病和心脏病住院患者的管理。方法在法赫德国王医疗城心脏中心进行前瞻性随机研究,纳入2019年至2023年入院的患者。参与者被分配到两组中的一组:一组由临床药师管理(n = 500),另一组接受没有临床药师的标准治疗(n = 500)。在临床药师的干预下,对患者进行了为期6个月的随访,同时收集数据、糖化血红蛋白(HbAC)基线测量、空腹血糖(FBG)和低血糖发作频率。后干预。同时,纳入(HbA1c),干预后。同时,收集包括(HbA1c),以下事件。结果两组均显示HbA1c水平下降。干预组HbA1c从10.2%降至8.5% (SD = 2.2, p = 0.04)。对照组HbA1c由9.95%降至9.05% (SD = 1.95, p = 0.05)。此外,干预组的空腹血糖(FBG)水平下降了29 mg/dL,而对照组的下降无统计学意义,为9 mg/dL。两组HbA1c水平的差异均具有统计学意义。结论临床药师作为多学科团队的一员,对住院心脏病患者的糖尿病监测具有重要作用。与标准治疗相比,他们的干预措施可以更有效地降低这些患者的HbA1c水平和空腹血糖(FBG)。
{"title":"The role of clinical pharmacists in improving diabetic care of hospitalized heart patients","authors":"Sanaa Mekdad,&nbsp;Leenah Alsayed,&nbsp;Susan Alkhulaif","doi":"10.1016/j.deman.2024.100248","DOIUrl":"10.1016/j.deman.2024.100248","url":null,"abstract":"<div><h3>Introduction</h3><div>Globally, diabetes is becoming an increasingly prevalent chronic illness. Managing glucose levels in patients with diabetes presents a significant challenge that requires collaboration with medical specialists. Clinical pharmacists play a crucial role in diabetes management, positively influencing patient outcomes and improving overall quality of care.</div></div><div><h3>Objectives</h3><div>The purpose of this research is to understand how clinical pharmacists at King Fahad Medical City impact the management of hospitalized patients with diabetes and cardiac conditions.</div></div><div><h3>Method</h3><div>A prospective randomized study was conducted at the Cardiac Center of King Fahad Medical City, involving patients admitted between 2019 and 2023. Participants were assigned to one of two groups: one managed by clinical pharmacists (<em>n</em> = 500) and the other receiving standard care without clinical pharmacists (<em>n</em> = 500). Patients were followed up with six months following the clinical pharmacist's intervention, as well as concurrently with data collection, baseline measurements of glycosylated hemoglobin (HbAC), fasting blood glucose (FBG), and the frequency of hypoglycemic episodes. after intervention. Concurrently, included (HbA1c), after intervention. Concurrently, collection included (HbA1c), episodes following the</div></div><div><h3>Results</h3><div>Both groups demonstrated a decrease in HbA1c levels. The intervention group experienced a reduction in HbA1c from 10.2 % to 8.5 % (SD = 2.2, <em>p</em> = 0.04). In contrast, the control group showed a decrease in HbA1c from 9.95 % to 9.05 % (SD = 1.95, <em>p</em> = 0.05). Additionally, fasting blood glucose (FBG) levels in the intervention group decreased by 29 mg/dL, while the decline in the control group was not statistically significant, at 9 mg/dL. The difference in HbA1c levels was statistically significant, as determined by both <em>t</em>-tests.</div></div><div><h3>Conclusions</h3><div>As a member of a multidisciplinary team, a clinical pharmacist can play a crucial role in monitoring diabetes in hospitalized patients with heart conditions. Their interventions can more effectively lower HbA1c levels and fasting blood glucose (FBG) in these patients compared to standard care.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100248"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ramadan fasting among adults with type 2 diabetes in five geographically different regions of the world: The DAR 2020 global survey 世界5个不同地理区域2型糖尿病成人斋月禁食:DAR 2020全球调查
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.deman.2024.100251
Sari Luthfiyah , Wannarat Lawang , Fathimath Shifaza
{"title":"Ramadan fasting among adults with type 2 diabetes in five geographically different regions of the world: The DAR 2020 global survey","authors":"Sari Luthfiyah ,&nbsp;Wannarat Lawang ,&nbsp;Fathimath Shifaza","doi":"10.1016/j.deman.2024.100251","DOIUrl":"10.1016/j.deman.2024.100251","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100251"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of oral health status in patients with type 2 diabetes 2型糖尿病患者口腔健康状况的评价
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.deman.2024.100250
Tahmineh Khoshbakhti , Vajehallah Raeesi , Gholamreza Sharifzadeh , Leili Alizadeh

Background

Type 2 diabetes is among the most prevalent endocrine disruptors. One of the most significant symptoms reported by diabetic patients is dry mouth, which results in reduced saliva buffering capacity and an increased risk of dental caries. So, the purpose of this study was to compare the oral health indicators of type 2 diabetic patients with non-diabetic controls.

Methods

In this case-control study, A total of 306 individuals included in the study (103 T2DM cases and 203 non-diabetic controls) in the age range of 40 to 60 years old. Participants were interviewed using a structured questionnaire including socio-demographics and oral health related to dry mouth factors. The clinical examination included full-mouth probing depths and an assessment of oral mucosal conditions to determine the DMFT index and identify any mucosal lesions. Data analysis was performed using SPSS software with a significance level set at 5 %.

Results

The patients had more probing depths >4 mm, tooth mobility, furcation involvement and missing teeth. The mean score of dry mouth and DMFT indexes were 3.38±2.64, 2.17±1.09 and 19.33±9.54, 15.48±6.93 in the case and control groups respectively. Also, the adjusted odds ratios (AOR) and their 95 % confidence Intervals (CI) reported a significant association as 2.96 (1.36–6.45), 5.90 (2.26–15.39), 0.23 (0.08–0.63) and 4.07 (1.74–9.49) for the above variables respectively.

Conclusion

Overall, the results of this study highlight that chronic periodontitis, tooth mobility, furcation and involvement were more prevalent among T2DM patients compared to non-diabetic controls. By recognizing these relationships and implementing targeted interventions, healthcare providers can improve oral health outcomes.
背景:2型糖尿病是最常见的内分泌干扰物之一。糖尿病患者报告的最显著症状之一是口干,这导致唾液缓冲能力降低,患龋齿的风险增加。因此,本研究的目的是比较2型糖尿病患者与非糖尿病对照组的口腔健康指标。方法本研究共纳入306例患者,其中T2DM患者103例,非糖尿病患者203例,年龄在40 ~ 60岁之间。参与者使用结构化问卷进行访谈,包括与口干相关的社会人口统计学和口腔健康因素。临床检查包括全口探探深度和口腔黏膜状况评估,以确定DMFT指数和确定任何粘膜病变。数据分析采用SPSS软件,显著性水平设为5%。结果患者探牙深度≥4mm,牙活动度高,分岔受累,缺牙。病例组和对照组口干评分和DMFT指数平均分别为3.38±2.64、2.17±1.09和19.33±9.54、15.48±6.93。调整后的优势比(AOR)及其95%置信区间(CI)分别为2.96(1.36-6.45)、5.90(2.26-15.39)、0.23(0.08-0.63)和4.07(1.74-9.49)。结论总体而言,本研究结果表明,与非糖尿病对照组相比,慢性牙周炎、牙齿移动、分叉和受累在T2DM患者中更为普遍。通过认识到这些关系并实施有针对性的干预措施,卫生保健提供者可以改善口腔健康结果。
{"title":"Evaluation of oral health status in patients with type 2 diabetes","authors":"Tahmineh Khoshbakhti ,&nbsp;Vajehallah Raeesi ,&nbsp;Gholamreza Sharifzadeh ,&nbsp;Leili Alizadeh","doi":"10.1016/j.deman.2024.100250","DOIUrl":"10.1016/j.deman.2024.100250","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes is among the most prevalent endocrine disruptors. One of the most significant symptoms reported by diabetic patients is dry mouth, which results in reduced saliva buffering capacity and an increased risk of dental caries. So, the purpose of this study was to compare the oral health indicators of type 2 diabetic patients with non-diabetic controls.</div></div><div><h3>Methods</h3><div>In this case-control study, A total of 306 individuals included in the study (103 T2DM cases and 203 non-diabetic controls) in the age range of 40 to 60 years old. Participants were interviewed using a structured questionnaire including socio-demographics and oral health related to dry mouth factors. The clinical examination included full-mouth probing depths and an assessment of oral mucosal conditions to determine the DMFT index and identify any mucosal lesions. Data analysis was performed using SPSS software with a significance level set at 5 %.</div></div><div><h3>Results</h3><div>The patients had more probing depths &gt;4 mm, tooth mobility, furcation involvement and missing teeth. The mean score of dry mouth and DMFT indexes were 3.38±2.64, 2.17±1.09 and 19.33±9.54, 15.48±6.93 in the case and control groups respectively. Also, the adjusted odds ratios (AOR) and their 95 % confidence Intervals (CI) reported a significant association as 2.96 (1.36–6.45), 5.90 (2.26–15.39), 0.23 (0.08–0.63) and 4.07 (1.74–9.49) for the above variables respectively.</div></div><div><h3>Conclusion</h3><div>Overall, the results of this study highlight that chronic periodontitis, tooth mobility, furcation and involvement were more prevalent among T2DM patients compared to non-diabetic controls. By recognizing these relationships and implementing targeted interventions, healthcare providers can improve oral health outcomes.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100250"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of intermittent fasting for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized trials 间歇性禁食治疗2型糖尿病的疗效和安全性:随机试验的系统回顾和荟萃分析
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.deman.2024.100249
Joshua Chadwick, Lavanya Ayyasamy, Madhanraj Kalyanasundaram, Ganeshkumar Parasuraman, Bhavani Shankara Bagepally, Jeyashree Kathiresan, Lokesh Shanmugam

Background & objectives

Type 2 diabetes mellitus (T2DM) is a pressing public health concern, contributing to 11 % of annual deaths and incurring direct expenses of $760 billion. Studies show intermittent fasting (IF) can effectively lower glycated haemoglobin (HbA1c) levels and reduce weight and levels in individuals with type 2 diabetes. The study's objective is to evaluate the efficacy and safety of IF on glycaemic control among patients with T2DM.

Methods

We conducted searches in the MEDLINE (Ovid), Embase, and SINOMED databases until February 29, 2024, focusing on glycaemic control as the outcome of interest. Secondary outcomes included changes in weight, and BMI (PROSPERO ID: CRD42022357598). We used a random effect model to synthesize the effect measure. We performed a sensitivity analysis to assess the robustness of the result.

Results

Out of the 24 studies identified, nine were deemed suitable for inclusion. Four studies, including 238 participants, were selected for the meta-analysis. The analysis revealed that IF and regular diets showed similar effects on glycemic control, HbA1c (−1.27 %, 95 % confidence interval [CI] −3.71 to 1.17) and fasting plasma glucose (−1.66, 95 % CI −4.22 to 0.90). Weight reduction outcomes were also similar between the two diets (−0.26, 95 % CI −1.43 to 0.91 kg). The frequency of hypoglycemic episodes was comparable across both groups.

Interpretation & conclusions

On the basis of moderate to low certainty of evidence, IF can be a safe dietary approach for patients with T2DM, with similar safety and effectiveness profiles to regular diets. However, larger-scale studies are recommended to confirm these findings.
背景,目的2型糖尿病(T2DM)是一个紧迫的公共卫生问题,每年造成11%的死亡,直接费用达7600亿美元。研究表明,间歇性禁食(IF)可以有效降低2型糖尿病患者的糖化血红蛋白(HbA1c)水平,减轻体重和水平。该研究的目的是评估IF对T2DM患者血糖控制的有效性和安全性。方法我们在MEDLINE (Ovid)、Embase和SINOMED数据库中进行检索,检索截止至2024年2月29日,重点关注血糖控制作为感兴趣的结果。次要结局包括体重和BMI的变化(PROSPERO ID: CRD42022357598)。我们采用随机效应模型来综合效应测度。我们进行了敏感性分析以评估结果的稳健性。结果在确定的24项研究中,有9项被认为适合纳入。四项研究,包括238名参与者,被选中进行meta分析。分析显示,IF和常规饮食对血糖控制、糖化血红蛋白(- 1.27%,95%可信区间[CI] - 3.71至1.17)和空腹血糖(- 1.66,95%可信区间[CI] - 4.22至0.90)的影响相似。两种饮食的减肥结果也相似(- 0.26,95% CI - 1.43至0.91 kg)。两组的低血糖发作频率具有可比性。解释,结论在中等至低证据确定性的基础上,IF可作为T2DM患者的一种安全的饮食方法,其安全性和有效性与常规饮食相似。然而,建议进行更大规模的研究来证实这些发现。
{"title":"Efficacy and safety of intermittent fasting for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized trials","authors":"Joshua Chadwick,&nbsp;Lavanya Ayyasamy,&nbsp;Madhanraj Kalyanasundaram,&nbsp;Ganeshkumar Parasuraman,&nbsp;Bhavani Shankara Bagepally,&nbsp;Jeyashree Kathiresan,&nbsp;Lokesh Shanmugam","doi":"10.1016/j.deman.2024.100249","DOIUrl":"10.1016/j.deman.2024.100249","url":null,"abstract":"<div><h3>Background &amp; objectives</h3><div>Type 2 diabetes mellitus (T2DM) is a pressing public health concern, contributing to 11 % of annual deaths and incurring direct expenses of $760 billion. Studies show intermittent fasting (IF) can effectively lower glycated haemoglobin (HbA1c) levels and reduce weight and levels in individuals with type 2 diabetes. The study's objective is to evaluate the efficacy and safety of IF on glycaemic control among patients with T2DM.</div></div><div><h3>Methods</h3><div>We conducted searches in the MEDLINE (Ovid), Embase, and SINOMED databases until February 29, 2024, focusing on glycaemic control as the outcome of interest. Secondary outcomes included changes in weight, and BMI (PROSPERO ID: CRD42022357598). We used a random effect model to synthesize the effect measure. We performed a sensitivity analysis to assess the robustness of the result.</div></div><div><h3>Results</h3><div>Out of the 24 studies identified, nine were deemed suitable for inclusion. Four studies, including 238 participants, were selected for the meta-analysis. The analysis revealed that IF and regular diets showed similar effects on glycemic control, HbA1c (−1.27 %, 95 % confidence interval [CI] −3.71 to 1.17) and fasting plasma glucose (−1.66, 95 % CI −4.22 to 0.90). Weight reduction outcomes were also similar between the two diets (−0.26, 95 % CI −1.43 to 0.91 kg). The frequency of hypoglycemic episodes was comparable across both groups.</div></div><div><h3>Interpretation &amp; conclusions</h3><div>On the basis of moderate to low certainty of evidence, IF can be a safe dietary approach for patients with T2DM, with similar safety and effectiveness profiles to regular diets. However, larger-scale studies are recommended to confirm these findings.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100249"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative immunotherapies and emerging treatments in type 1 diabetes management 1 型糖尿病管理中的创新免疫疗法和新兴疗法
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-11-13 DOI: 10.1016/j.deman.2024.100247
Malek Zarei , Mohammad Abbas Sheikholeslami , Masoud Mozaffari , Yassar Mortada
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease characterized by the selective destruction of pancreatic insulin-producing beta cells, primarily mediated by CD4+ and CD8+ T cells. This review comprehensively examines the latest advances in immunotherapeutic approaches to T1D, categorizing current strategies into four main groups: antigen-independent therapies, antigen-dependent therapies, beta cell therapies, and stem cell therapies. Antigen-independent strategies, such as antibody-based therapies (e.g., Abatacept and Teplizumab) and cytokine inhibitors (e.g., Anakinra and Etanercept), have shown potential in preserving beta cell function by modulating immune responses. Antigen-dependent strategies focus on inducing immune tolerance to specific beta cell antigens, with mixed results from clinical trials involving autoantigen vaccines like GAD65. Beta cell therapies, including islet transplantation, offer promising outcomes but face challenges related to immunosuppression and donor availability. Stem cell therapies, particularly using mesenchymal stem cells (MSCs) and autologous hematopoietic stem cells (HSCs), demonstrate potential in immune modulation and beta cell regeneration. Novel approaches, such as Chimeric Antigen Receptor (CAR)–Tregs therapy and JAK-STAT pathway inhibition, represent exciting areas of ongoing research. This comprehensive overview underscores the necessity of personalized therapeutic approaches and continued research to optimize existing therapies and explore new targets, ultimately aiming to improve outcomes and achieve a potential cure for T1D.
1 型糖尿病(T1D)是一种慢性自身免疫性疾病,主要由 CD4+ 和 CD8+ T 细胞介导,以选择性破坏胰岛分泌胰岛素的 beta 细胞为特征。本综述全面探讨了治疗 T1D 的免疫疗法的最新进展,并将目前的疗法分为四大类:抗原依赖性疗法、抗原依赖性疗法、β 细胞疗法和干细胞疗法。抗原依赖型疗法,如抗体疗法(如阿巴他赛普和替普利珠单抗)和细胞因子抑制剂(如阿纳金拉和依那西普),已显示出通过调节免疫反应保护β细胞功能的潜力。抗原依赖性策略侧重于诱导对特定β细胞抗原的免疫耐受,涉及自身抗原疫苗(如 GAD65)的临床试验结果喜忧参半。β细胞疗法(包括胰岛移植)的疗效很好,但也面临着免疫抑制和供体供应方面的挑战。干细胞疗法,特别是使用间充质干细胞(MSCs)和自体造血干细胞(HSCs)的疗法,在免疫调节和β细胞再生方面显示出潜力。嵌合抗原受体(CAR)-Tregs疗法和JAK-STAT通路抑制等新方法是令人兴奋的研究领域。这一全面概述强调了个性化治疗方法和持续研究的必要性,以优化现有疗法并探索新的靶点,最终改善治疗效果并实现治愈 T1D 的可能。
{"title":"Innovative immunotherapies and emerging treatments in type 1 diabetes management","authors":"Malek Zarei ,&nbsp;Mohammad Abbas Sheikholeslami ,&nbsp;Masoud Mozaffari ,&nbsp;Yassar Mortada","doi":"10.1016/j.deman.2024.100247","DOIUrl":"10.1016/j.deman.2024.100247","url":null,"abstract":"<div><div>Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease characterized by the selective destruction of pancreatic insulin-producing beta cells, primarily mediated by CD4+ and CD8+ T cells. This review comprehensively examines the latest advances in immunotherapeutic approaches to T1D, categorizing current strategies into four main groups: antigen-independent therapies, antigen-dependent therapies, beta cell therapies, and stem cell therapies. Antigen-independent strategies, such as antibody-based therapies (e.g., Abatacept and Teplizumab) and cytokine inhibitors (e.g., Anakinra and Etanercept), have shown potential in preserving beta cell function by modulating immune responses. Antigen-dependent strategies focus on inducing immune tolerance to specific beta cell antigens, with mixed results from clinical trials involving autoantigen vaccines like GAD65. Beta cell therapies, including islet transplantation, offer promising outcomes but face challenges related to immunosuppression and donor availability. Stem cell therapies, particularly using mesenchymal stem cells (MSCs) and autologous hematopoietic stem cells (HSCs), demonstrate potential in immune modulation and beta cell regeneration. Novel approaches, such as Chimeric Antigen Receptor (CAR)–Tregs therapy and JAK-STAT pathway inhibition, represent exciting areas of ongoing research. This comprehensive overview underscores the necessity of personalized therapeutic approaches and continued research to optimize existing therapies and explore new targets, ultimately aiming to improve outcomes and achieve a potential cure for T1D.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100247"},"PeriodicalIF":1.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoantibodies in type 1 diabetes: Prevalence and clinical profiles 1 型糖尿病的自身抗体:发病率和临床特征
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-29 DOI: 10.1016/j.deman.2024.100246
Raja Hazime , Saad Lamjadli , Morad Guennouni , Mounir Belkrachni , Fatima-Ezzohra Eddehbi , Ider Oujamaa , Lahcen Elmoumou , Aicha Bourrahouate , Imane Ait Sab , Hicham Baizri , Nawal El Ansari , Brahim Admou
Type 1 diabetes mellitus (T1D) is one of the most common chronic diseases in children and is associated with acute and serious chronic complications. T1D is characterized by the destruction of insulin-producing beta cells in the pancreas, with the emergence of circulating autoantibodies (a-Abs) targeting β cell antigens. Identifying autoantibodies can help predict the onset of T1D and associated autoimmune disorders, enhancing patient management strategies.
We aimed to determine the prevalence of T1D autoantibodies and their clinical significance in the pediatric and adult populations. A multicenter cross-sectional study was carried out on 276 patient-first with T1D, including 167 pediatric (60.5 %) and 109 adult (39.5 %) cases, of which 144 were female and 132 were male (sex ratio= 0.91),with an average age of 14.1 ± 8.0 years. The immunological investigation was based on the detection of T1D related a-Abs, including anti-insulin, anti-glutamic acid decarboxylase (GAD65), anti-insulinoma-associated antigen 2 (IA2), and anti-zinc transporter 8 (ZnT8) specificities. The results revealed an overall autoantibody seropositivity rate of 75.36 % (n= 208). Among the positive cases, GAD65 antibodies were the most prevalent at 37.31 %, followed by anti-insulin and anti-ZnT8 antibodies, each at 36.59 %, and anti-IA2 at 28.62 %. Additionally, 45,67 % of patients had one a-Abs, 28.36 % had a two, 21.15 % had three, and 4.8 % had all four a-Abs.
A statistically significant difference was observed between the seropositive and seronegative groups regarding the presence of associated autoimmune diseases (p = 0.005). These findings align with the existing literature, highlighting the importance and scientific value of detecting a-Abs in patients with T1D.
1 型糖尿病(T1D)是儿童最常见的慢性疾病之一,并伴有急性和严重的慢性并发症。T1D的特征是胰腺中产生胰岛素的β细胞遭到破坏,同时出现针对β细胞抗原的循环自身抗体(a-Abs)。识别自身抗体有助于预测 T1D 和相关自身免疫性疾病的发病,从而改善患者管理策略。我们的目的是确定 T1D 自身抗体在儿童和成人人群中的流行率及其临床意义。我们对276名T1D患者进行了多中心横断面研究,包括167名儿童(60.5%)和109名成人(39.5%),其中女性144名,男性132名(性别比= 0.91),平均年龄为(14.1 ± 8.0)岁。免疫学调查的基础是检测与 T1D 相关的 a-抗体,包括抗胰岛素、抗谷氨酸脱羧酶(GAD65)、抗胰岛素瘤相关抗原 2(IA2)和抗锌转运体 8(ZnT8)特异性抗体。结果显示,总体自身抗体血清阳性率为 75.36%(n= 208)。在阳性病例中,GAD65 抗体最普遍,占 37.31%,其次是抗胰岛素抗体和抗 ZnT8 抗体,各占 36.59%,抗 IA2 抗体占 28.62%。此外,45.67% 的患者有一种 a 抗体,28.36% 的患者有两种,21.15% 的患者有三种,4.8% 的患者有四种 a 抗体。这些研究结果与现有文献一致,强调了在 T1D 患者中检测 a-Abs 的重要性和科学价值。
{"title":"Autoantibodies in type 1 diabetes: Prevalence and clinical profiles","authors":"Raja Hazime ,&nbsp;Saad Lamjadli ,&nbsp;Morad Guennouni ,&nbsp;Mounir Belkrachni ,&nbsp;Fatima-Ezzohra Eddehbi ,&nbsp;Ider Oujamaa ,&nbsp;Lahcen Elmoumou ,&nbsp;Aicha Bourrahouate ,&nbsp;Imane Ait Sab ,&nbsp;Hicham Baizri ,&nbsp;Nawal El Ansari ,&nbsp;Brahim Admou","doi":"10.1016/j.deman.2024.100246","DOIUrl":"10.1016/j.deman.2024.100246","url":null,"abstract":"<div><div>Type 1 diabetes mellitus (T1D) is one of the most common chronic diseases in children and is associated with acute and serious chronic complications. T1D is characterized by the destruction of insulin-producing beta cells in the pancreas, with the emergence of circulating autoantibodies (a-Abs) targeting β cell antigens. Identifying autoantibodies can help predict the onset of T1D and associated autoimmune disorders, enhancing patient management strategies.</div><div>We aimed to determine the prevalence of T1D autoantibodies and their clinical significance in the pediatric and adult populations. A multicenter cross-sectional study was carried out on 276 patient-first with T1D, including 167 pediatric (60.5 %) and 109 adult (39.5 %) cases, of which 144 were female and 132 were male (sex ratio= 0.91),with an average age of 14.1 ± 8.0 years. The immunological investigation was based on the detection of T1D related a-Abs, including anti-insulin, anti-glutamic acid decarboxylase (GAD65), anti-insulinoma-associated antigen 2 (IA2), and anti-zinc transporter 8 (ZnT8) specificities. The results revealed an overall autoantibody seropositivity rate of 75.36 % (n= 208). Among the positive cases, GAD65 antibodies were the most prevalent at 37.31 %, followed by anti-insulin and anti-ZnT8 antibodies, each at 36.59 %, and anti-IA2 at 28.62 %. Additionally, 45,67 % of patients had one a-Abs, 28.36 % had a two, 21.15 % had three, and 4.8 % had all four a-Abs.</div><div>A statistically significant difference was observed between the seropositive and seronegative groups regarding the presence of associated autoimmune diseases (p = 0.005). These findings align with the existing literature, highlighting the importance and scientific value of detecting a-Abs in patients with T1D.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100246"},"PeriodicalIF":1.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142657375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to increase in diabetic deaths during COVID-19 pandemic. Some comments 对 COVID-19 大流行期间糖尿病死亡人数增加的答复。一些评论
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-15 DOI: 10.1016/j.deman.2024.100240
Camilla Mattiuzzi, Giuseppe Lippi
{"title":"Reply to increase in diabetic deaths during COVID-19 pandemic. Some comments","authors":"Camilla Mattiuzzi,&nbsp;Giuseppe Lippi","doi":"10.1016/j.deman.2024.100240","DOIUrl":"10.1016/j.deman.2024.100240","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100240"},"PeriodicalIF":1.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High prevalence of prediabetes and type 2 diabetes, and identification of associated factors, in high-risk adults in Vietnam: A cross-sectional study 越南高危成年人中糖尿病前期和 2 型糖尿病的高发病率以及相关因素的识别:横断面研究
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-09 DOI: 10.1016/j.deman.2024.100239
Tran Bao Vuong , Triet Minh Tran , Nam Quang Tran

Objectives

The prevalences of diabetes and prediabetes have increased rapidly in recent years in emerging nations such as Vietnam, particularly in the population at high risk of diabetes. This study aimed to investigate the prevalence of prediabetes and undiagnosed diabetes in individuals at high risk of type 2 diabetes (T2D), as well as the related risk factors.

Methods

This cross-sectional study at the clinics of the University Medical Center in Ho Chi Minh City included 360 patients who were 18 years of age or older, and were at risk of developing T2D. The diagnosis of prediabetes and diabetes relied on measurements of fasting plasma glucose, HbA1c, and 2-hour plasma glucose after a 75 g oral glucose tolerance test.

Results

The prevalence of prediabetes was 60.6 % (95 % CI: 55.3–65.6 %), and the prevalence of diabetes was 18.3 % (95 % CI: 14.6–22.8 %). Older age (OR = 1.06), obesity (OR = 3.89), hypertension (OR = 5.71), and dyslipidemia (OR = 2.01) were factors associated with increasing frequencies of undiagnosed T2D and prediabetes.

Conclusion

The prevalences of prediabetes and undiagnosed diabetes were significantly higher among people with a high-risk of dysglycemia in Vietnam. There is a need for screening programs for such high-risk individuals.
目的近年来,在越南等新兴国家,糖尿病和糖尿病前期的发病率迅速上升,尤其是在糖尿病高危人群中。本研究旨在调查 2 型糖尿病(T2D)高风险人群中糖尿病前期和未确诊糖尿病的患病率,以及相关风险因素。方法这项横断面研究在胡志明市大学医疗中心诊所进行,共纳入 360 名年龄在 18 岁或以上、有患 T2D 风险的患者。糖尿病前期和糖尿病的诊断依赖于空腹血浆葡萄糖、HbA1c 和 75 克口服葡萄糖耐量试验后 2 小时血浆葡萄糖的测量结果。结果糖尿病前期的患病率为 60.6%(95 % CI:55.3-65.6%),糖尿病的患病率为 18.3%(95 % CI:14.6-22.8%)。高龄(OR = 1.06)、肥胖(OR = 3.89)、高血压(OR = 5.71)和血脂异常(OR = 2.01)是未确诊 T2D 和糖尿病前期发病率增加的相关因素。有必要针对此类高危人群开展筛查计划。
{"title":"High prevalence of prediabetes and type 2 diabetes, and identification of associated factors, in high-risk adults in Vietnam: A cross-sectional study","authors":"Tran Bao Vuong ,&nbsp;Triet Minh Tran ,&nbsp;Nam Quang Tran","doi":"10.1016/j.deman.2024.100239","DOIUrl":"10.1016/j.deman.2024.100239","url":null,"abstract":"<div><h3>Objectives</h3><div>The prevalences of diabetes and prediabetes have increased rapidly in recent years in emerging nations such as Vietnam, particularly in the population at high risk of diabetes. This study aimed to investigate the prevalence of prediabetes and undiagnosed diabetes in individuals at high risk of type 2 diabetes (T2D), as well as the related risk factors.</div></div><div><h3>Methods</h3><div>This cross-sectional study at the clinics of the University Medical Center in Ho Chi Minh City included 360 patients who were 18 years of age or older, and were at risk of developing T2D. The diagnosis of prediabetes and diabetes relied on measurements of fasting plasma glucose, HbA1c, and 2-hour plasma glucose after a 75 g oral glucose tolerance test.</div></div><div><h3>Results</h3><div>The prevalence of prediabetes was 60.6 % (95 % CI: 55.3–65.6 %), and the prevalence of diabetes was 18.3 % (95 % CI: 14.6–22.8 %). Older age (OR = 1.06), obesity (OR = 3.89), hypertension (OR = 5.71), and dyslipidemia (OR = 2.01) were factors associated with increasing frequencies of undiagnosed T2D and prediabetes.</div></div><div><h3>Conclusion</h3><div>The prevalences of prediabetes and undiagnosed diabetes were significantly higher among people with a high-risk of dysglycemia in Vietnam. There is a need for screening programs for such high-risk individuals.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100239"},"PeriodicalIF":1.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142434305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increase in diabetic deaths during COVID-19 pandemic. Some comments COVID-19 大流行期间糖尿病死亡人数增加。一些评论
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-28 DOI: 10.1016/j.deman.2024.100238
Salvatore Chirumbolo
{"title":"Increase in diabetic deaths during COVID-19 pandemic. Some comments","authors":"Salvatore Chirumbolo","doi":"10.1016/j.deman.2024.100238","DOIUrl":"10.1016/j.deman.2024.100238","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100238"},"PeriodicalIF":1.0,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of vitamin D status in obese and non-obese patients: A case-control study 评估肥胖和非肥胖患者的维生素 D 状态:病例对照研究
IF 1 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-12 DOI: 10.1016/j.deman.2024.100237
Salma Derbel , Lamiae Zarraa , Imane Assarrar , Nisrine Bouichrat , Siham Rouf , Hanane Latrech

Background

Vitamin D is an essential component of healthy bones and its deficiency is widespread in obese patients. Through our study, we aimed to look into vitamin D status in obese and non-obese patients and determine its association with hypertension, glucose levels, and lipid profiles.

Patients and methods

A case-control study was laid out to compare serum Vitamin D levels between obese patients and controls. Obese patients (n= 67) over 18 years old were recruited from our Endocrinology-Diabetology and Nutrition department between March 2018 and September 2023. Controls (n = 60) were randomly assigned and were matched for age, sex, glycated hemoglobin, ethnicity, and geographic area. The levels of Vitamin D in the serum were determined in obese patients and non-obese controls.

Results

Average serum Vitamin D concentration was established in both groups, reaching 10,41±4,2 ng/ml in obese patients and 15,14±6,1 ng/ml in the control group. The mean serum Vitamin D was significantly lower in the obese group (p = 0,000). A positive correlation was noticed between body fat and serum Vitamin D (p < 0,05). A significant correlation between vitamin D status and glycated hemoglobin in the obese group (p = 0,047) was found, whereas it was insignificant in the control group (p = 0,966). In addition, the correlation between vitamin D, blood pressure, and body mass index was significant (p = 0.004) as well as between vitamin D and triglycerides (p = 0.015) and cholesterol (p = 0.014).

Conclusion

Vitamin D deficiency is common in obese patients, as highlighted by our study, which is in line with other findings. This may be explained by the fact that vitamin D must be supplied at a greater volume in obese patients. A significant correlation between BMI, vitamin D, glycated hemoglobin, blood pressure, triglycerides, and total cholesterol was found. The pathophysiology behind this association is complex. Further research is needed to clarify the relationship between vitamin D, adipose tissue, and the other components of metabolic syndrome.

背景维生素 D 是健康骨骼的重要组成部分,肥胖患者普遍缺乏维生素 D。我们的研究旨在调查肥胖和非肥胖患者的维生素 D 状态,并确定其与高血压、血糖水平和血脂状况的关系。患者和方法我们开展了一项病例对照研究,以比较肥胖患者和对照组的血清维生素 D 水平。2018年3月至2023年9月期间,本院内分泌科-糖尿病与营养科招募了18岁以上的肥胖患者(n=67)。对照组(n=60)为随机分配,在年龄、性别、糖化血红蛋白、种族和地理区域方面均匹配。测定了肥胖患者和非肥胖对照组血清中维生素 D 的水平。结果两组患者的平均血清维生素 D 浓度均为 10,41±4,2 纳克/毫升(肥胖患者)和 15,14±6,1 纳克/毫升(对照组)。肥胖组的血清维生素 D 平均值明显较低(p = 0,000)。体脂与血清维生素 D 之间呈正相关(p < 0,05)。肥胖组的维生素 D 状态与糖化血红蛋白之间存在明显的相关性(p = 0,047),而对照组的相关性不明显(p = 0,966)。此外,维生素 D、血压和体重指数之间的相关性显著(p = 0.004),维生素 D 与甘油三酯(p = 0.015)和胆固醇(p = 0.014)之间的相关性也显著。这可能是因为肥胖患者必须摄入更多的维生素 D。研究发现,体重指数、维生素 D、糖化血红蛋白、血压、甘油三酯和总胆固醇之间存在明显的相关性。这种关联背后的病理生理学非常复杂。还需要进一步的研究来阐明维生素 D、脂肪组织和代谢综合征其他成分之间的关系。
{"title":"Assessment of vitamin D status in obese and non-obese patients: A case-control study","authors":"Salma Derbel ,&nbsp;Lamiae Zarraa ,&nbsp;Imane Assarrar ,&nbsp;Nisrine Bouichrat ,&nbsp;Siham Rouf ,&nbsp;Hanane Latrech","doi":"10.1016/j.deman.2024.100237","DOIUrl":"10.1016/j.deman.2024.100237","url":null,"abstract":"<div><h3>Background</h3><p>Vitamin D is an essential component of healthy bones and its deficiency is widespread in obese patients. Through our study, we aimed to look into vitamin D status in obese and non-obese patients and determine its association with hypertension, glucose levels, and lipid profiles.</p></div><div><h3>Patients and methods</h3><p>A case-control study was laid out to compare serum Vitamin D levels between obese patients and controls. Obese patients (<em>n</em>= 67) over 18 years old were recruited from our Endocrinology-Diabetology and Nutrition department between March 2018 and September 2023. Controls (<em>n</em> = 60) were randomly assigned and were matched for age, sex, glycated hemoglobin, ethnicity, and geographic area. The levels of Vitamin D in the serum were determined in obese patients and non-obese controls.</p></div><div><h3>Results</h3><p>Average serum Vitamin D concentration was established in both groups, reaching 10,41±4,2 ng/ml in obese patients and 15,14±6,1 ng/ml in the control group. The mean serum Vitamin D was significantly lower in the obese group (<em>p</em> = 0,000). A positive correlation was noticed between body fat and serum Vitamin D (<em>p</em> &lt; 0,05). A significant correlation between vitamin D status and glycated hemoglobin in the obese group (<em>p</em> = 0,047) was found, whereas it was insignificant in the control group (<em>p</em> = 0,966). In addition, the correlation between vitamin D, blood pressure, and body mass index was significant (<em>p</em> <em>=</em> 0.004) as well as between vitamin D and triglycerides (<em>p</em> <em>=</em> 0.015) and cholesterol (<em>p</em> <em>=</em> 0.014).</p></div><div><h3>Conclusion</h3><p>Vitamin D deficiency is common in obese patients, as highlighted by our study, which is in line with other findings. This may be explained by the fact that vitamin D must be supplied at a greater volume in obese patients. A significant correlation between BMI, vitamin D, glycated hemoglobin, blood pressure, triglycerides, and total cholesterol was found. The pathophysiology behind this association is complex. Further research is needed to clarify the relationship between vitamin D, adipose tissue, and the other components of metabolic syndrome.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"17 ","pages":"Article 100237"},"PeriodicalIF":1.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666970624000416/pdfft?md5=6312261234fdc2e5e815735d8c34c4e9&pid=1-s2.0-S2666970624000416-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Diabetes epidemiology and management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1